featured
Examining the Economic Implications of the EMPA-REG OUTCOME Trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetic Medicine: A Journal of the British Diabetic Association
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cost‐Effectiveness Analysis of Empagliflozin Treatment in People With Type 2 Diabetes and Established Cardiovascular Disease in the EMPA‐REG OUTCOME Trial
Diabet. Med. 2019 Jul 11;[EPub Ahead of Print], A Kansal, OS Reifsnider, I Proskorovsky, Y Zheng, E Pfarr, JT George, P Kandaswamy, A RuffoloFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.